Aarti Drugs Limited

NSE AARTIDRUGS.NS

Aarti Drugs Limited Gross Profit for the year ending March 31, 2024: USD 42.10 M

Aarti Drugs Limited Gross Profit is USD 42.10 M for the year ending March 31, 2024, a -58.19% change year over year. Gross profit is the difference between revenue and the cost of revenue, representing the profit earned from core business operations.
  • Aarti Drugs Limited Gross Profit for the year ending March 31, 2023 was USD 100.69 M, a 51.74% change year over year.
  • Aarti Drugs Limited Gross Profit for the year ending March 31, 2022 was USD 66.35 M, a -19.07% change year over year.
  • Aarti Drugs Limited Gross Profit for the year ending March 31, 2021 was USD 81.98 M, a 52.83% change year over year.
  • Aarti Drugs Limited Gross Profit for the year ending March 31, 2020 was USD 53.65 M, a 18.85% change year over year.
Key data
Date Gross Profit Operating Income EBIT EBITDA
Market news
Loading...
NSE: AARTIDRUGS.NS

Aarti Drugs Limited

CEO Mr. Prakash Moreshwar Patil
IPO Date Sept. 19, 2003
Location India
Headquarters Mahendra Industrial Estate
Employees 1,064
Sector Health Care
Industries
Description

Aarti Drugs Limited, through its subsidiaries, engages in the pharmaceuticals business in India and internationally. The company offers active pharmaceutical ingredients in various therapeutic categories, including anti-inflammatory, cardioprotectants, antidiarrhoeals, antifungals, antiarthritis/osteoporosis, antibiotics, antidiabetics, Alzheimer's treatment, sedatives, vitamins, and alcoholism treatment; and pharmaceutical intermediate products comprising tinidazole, celecoxib, ciprofloxacin, clopidogrel, diclofenac, ketoconazole, nimesulide, and raloxifene. It also offers specialty chemical products, such as benzene sulphonamide, benzene sulphonic acid, benzene sulphonic acid methyl ester, benzene sulphonyl chloride, cipro Q acid, levofloxacin Q acid, methyl nicotinate, N-methyl methane sulphonamide, diphenyl sulphone, norofloxacin Q acid, ofloxacin Q acid, ortho para toluene sulphonamide, ortho/para toluene sulphonic acid methyl ester, para chloro benzene sulphonamide, para chloro benzene sulphonyl chloride, para toluene sulphonamide, para toluene sulphonic acid methyl ester, para toluene sulphonyl chloride, and sodium benezene sulfinate, as well as para toluene sulphonyl hydrazide and benzene sulphonic acid and sodium salt; and benzyl nicotinate, bisphenol – C, bisphenol – C(chloride), ethyl nicotinate, ethyl para toluene sulphonate, and N-methyl imidazole. In addition, the company's products under development comprise Acamprosate for alcoholism; Dabigatran for use as an anticoagulant; Sevelamer for antihyperphosphatemia; Colsevelam for anti-cholestrol treatment; Drondarone and Olmesartan for the treatment of cardiovascular diseases; Valasartan for use as cardiprotectant; and Sitagliptin for use as an antidiabetic. Further, it offers contract manufacturing services. The company was incorporated in 1984 and is headquartered in Mumbai, India.

Similar companies

APLLTD.NS

Alembic Pharmaceuticals Limited

USD 11.66

0.86%

AARTIIND.NS

Aarti Industries Limited

USD 4.73

0.12%

LAURUSLABS.NS

Laurus Labs Limited

USD 6.56

1.75%

ALKYLAMINE.NS

Alkyl Amines Chemicals Limited

USD 20.39

2.42%

IOLCP.NS

IOL Chemicals and Pharmaceuticals Limited

USD 4.56

4.65%

StockViz Staff

January 15, 2025

Any question? Send us an email